Cancer atrophicans, also known as atrophic cancer, is a rare and in most cases irreversible condition characterized by the progressive degeneration and shrinkage of a malignant tumor. This term is typically used in the field of dermatology, specifically in relation to cutaneous malignancies.
Atrophic cancer occurs when a malignant tumor, often skin cancer, undergoes a process of regression and diminishing in size over time. This shrinkage is accompanied by a reduction in the number of cancer cells, leading to the atrophy and thinning of the affected tissue. As a consequence of the regression, the tumor loses some of its malignant characteristics and can become less aggressive.
The exact cause of cancer atrophicans is not yet fully understood, but it is believed to be influenced by a multitude of factors, including the body's immune response to the tumor and certain therapeutic interventions such as radiation or chemotherapy.
Clinically, cancer atrophicans presents as a pale, depressed, and often indurated lesion that appears smaller and less prominent than before. It may also exhibit signs of inflammation, scarring, or ulceration. Depending on the specific tumor type and location, this condition can manifest differently.
Although atrophic cancer is typically considered a positive outcome for individuals with malignancies, it is important to note that it does not imply complete eradication of cancer cells. Continued monitoring and surveillance are therefore necessary to ensure the condition does not recur or progress.
